BMO Capital Maintains Outperform on Gilead Sciences, Raises Price Target to $85
Portfolio Pulse from Benzinga Newsdesk
BMO Capital analyst Evan Seigerman maintains an Outperform rating on Gilead Sciences (NASDAQ:GILD) and raises the price target from $80 to $85.
August 09, 2024 | 11:53 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BMO Capital analyst Evan Seigerman maintains an Outperform rating on Gilead Sciences and raises the price target from $80 to $85.
The raised price target and maintained Outperform rating from a reputable analyst at BMO Capital is likely to positively impact Gilead Sciences' stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100